ETNB stock forecast, quote, news & analysis
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases... Show more
ETNB saw its Stochastic Oscillator peaks and leaves the overbought zone
The Stochastic Oscillator for ETNB moved out of overbought territory on November 04, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 58 similar instances where the indicator exited the overbought zone. In of the 58 cases the stock moved lower. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
ETNB broke above its upper Bollinger Band on October 29, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ETNB advanced for three days, in of 266 cases, the price rose further within the following month. The odds of a continued upward trend are .
Advertisement
General Information
a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases
Industry Biotechnology